ArticleClinical nuclear medicine2026
Validation of the PSMA PRIMARY Scoring System and Comparison to an E-PSMA Likert System for [68Ga]Ga-PSMA-11 PET/CT Interpretation in Men With Suspected Radiorecurrent Prostate Cancer.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo validate the recently published 5-point PRIMARY scoring system against a 5-point European Association of Nuclear Medicine (E-PSMA) Likert system for the detection of intraprostatic recurrence for patients undergoing [68Ga]Ga-PSMA-11 PET/CT who have previously received radiotherapy for prostate cancer as their primary treatment. PATIENTS AND
methodsThirty-five patients from one centre were investigated for suspected radiorecurrence between 2016 and 2022. All patients underwent multiparametric MRI and [68Ga]Ga-PSMA-11 PET/CT for staging, then prostate biopsy. Analyses were performed at the hemi-gland level. Two expert readers, blinded to other clinical, pathologic, and radiologic data, independently assigned each hemi-gland an E-PSMA Likert and PRIMARY score. Outcomes were comparative diagnostic accuracy metrics and interreader agreement for each system at the hemi-gland level. Scores of 3-5 were considered suspicious for intraprostatic cancer.
resultsOf 70 hemi-glands, 43 (61%) had cancer on biopsy. Area under the curve was high and not statistically significantly different between systems (E-PSMA Likert: 0.84; 95% CI: 0.74-0.92; PRIMARY: 0.82; 95% CI: 0.71-0.91; P = 0.7). Sensitivity for E-PSMA Likert was 0.89 (95% CI: 0.78-0.96), not statistically different compared with the PRIMARY system (0.79; 95% CI: 0.67-0.89; P = 0.3). Specificity for the E-PSMA Likert system was 0.67 (95% CI: 0.46-0.86), not statistically different compared with the PRIMARY system (0.78; 95% CI: 0.60-0.91; P = 0.1). There was substantial interreader agreement between each reader for both E-PSMA Likert (κ = 0.65; 95% CI: 0.44-0.83) and PRIMARY systems (κ = 0.74; 95% CI: 0.59-0.90).
conclusionsIn patients with biochemical recurrence after primary radiotherapy for prostate cancer, both the 5-point PRIMARY and E-PSMA Likert scoring systems score demonstrated good performance and substantial interreader agreement between experts for the detection of intraprostatic recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.